Review




Structured Review

Chiron Corporation rhil 2
Rhil 2, supplied by Chiron Corporation, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rhil-2/2+rhil/us12533338-31-16-18
Average 86 stars, based on 1 article reviews
rhil 2 - by Bioz Stars, 2026-09
86/100 stars

Images

Related Articles

In Vitro:

Article Title: Evolution of melanoma cross-resistance to CD8 + T cells and MAPK inhibition in the course of BRAFi treatment
Article Snippet: Expansion of TILs was achieved by culturing suspension cells from tumor tissue in RPMI 1640 supplemented with 10% FCS, penicillin/streptomycin, and 500 IU/ml rhIL-2 (Chiron Corporation) for 2–5 weeks.

Article Title: The IL-2 SYNTHORIN molecule promotes functionally adapted Tregs in a preclinical model of type 1 diabetes.
Article Snippet: To investigate the in vitro effects of SAR’336 (Sanofi) on Tregs, purified CD4+GFP+ Tregs (GFP+, 50 × 103) from B6.FoxP3GFPki female mice were activated in 96-well, flat-bottomed (0.2 mL) plates previously coated with α-CD3 (3 μg/mL) and α-CD28 (2 μg/mL), in the presence of rhIL-2 (1 μg/mL; Chiron Corporation) or SAR’336 (1 μg/mL) in RPMI supplemented with 10% FBS at 37°C for 72 hours.

Article Title: The IL-2 SYNTHORIN molecule promotes functionally adapted Tregs in a preclinical model of type 1 diabetes
Article Snippet: To investigate the in vitro effects of SAR’336 (Sanofi) on Tregs, purified CD4 + GFP + Tregs (GFP + , 50 × 10 3 ) from B6.FoxP3 GFPki female mice were activated in 96-well, flat-bottomed (0.2 mL) plates previously coated with α-CD3 (3 μg/mL) and α-CD28 (2 μg/mL), in the presence of rhIL-2 (1 μg/mL; Chiron Corporation) or SAR’336 (1 μg/mL) in RPMI supplemented with 10% FBS at 37°C for 72 hours.

Article Title: Genetically engineered macrophages persist in solid tumors and locally deliver therapeutic proteins to activate immune responses
Article Snippet: T cells were stimulated with Dynabeads and cultured in RPMI-1640 (Gibco) with 10% FBS (VWR Seradigm), 2 mM l-glutamine (Gibco), 0.5 ng/mL rhIL-15 (Miltenyi Biotec) and either 50 U/mL rhIL-2 (CD8 + T cells; Chiron Corporation) or 5 ng/mL rhIL-7 (CD4 + T cells; Miltenyi Biotec).

Article Title: Cancer-Initiating Cells from Colorectal Cancer Patients Escape from T Cell–Mediated Immunosurveillance In Vitro through Membrane-Bound IL-4
Article Snippet: IL-4 neutralization can augment the proliferation of MLTCs stimulated with autologous CICs Isolation of CRC-reactive T lymphocytes PBMCs from the peripheral blood of CRC patients (#1076, 1247, and 14583) were cultured in vitro in the presence of autologous irradiated (300 Gy) colorectal CICs or, when available, FBS tumor cells, pretreated or not with rhIFN-γ (1000 IU/ml; PeproTech), with 100 IU/ml rhIL-2 (Chiron Corporation, Emeryville, CA) and 10 ng/ml rhIL-7 (PeproTech) in X-VIVO-15 (Cambrex, Lonza, Basel, Switzerland) plus 5% human serum.

Article Title: Cancer-Initiating Cells from Colorectal Cancer Patients Escape from T Cell–Mediated Immunosurveillance In Vitro through Membrane-Bound IL-4
Article Snippet: PBMCs from the peripheral blood of CRC patients (#1076, 1247, and 14583) were cultured in vitro in the presence of autologous irradiated (300 Gy) colorectal CICs or, when available, FBS tumor cells, pretreated or not with rhIFN-γ (1000 IU/ml; PeproTech), with 100 IU/ml rhIL-2 (Chiron Corporation, Emeryville, CA) and 10 ng/ml rhIL-7 (PeproTech) in X-VIVO-15 (Cambrex, Lonza, Basel, Switzerland) plus 5% human serum.

Article Title: Genetically engineered macrophages persist in solid tumors and locally deliver therapeutic proteins to activate immune responses.
Article Snippet: T cells were stimulated with Dynabeads and cultured in RPMI-1640 (Gibco) with 10% FBS (VWR Seradigm), 2 mM l- glutamine (Gibco), 0.5 ng/mL rhIL-15 (Miltenyi Biotec) and either 50 U/ mL rhIL-2 (CD8+ T cells; Chiron Corporation) or 5 ng/ mL rhIL-7 (CD4+ T cells; Miltenyi Biotec).

Article Title: Modulation of SRSF2 expression reverses the exhaustion of TILs via the epigenetic regulation of immune checkpoint molecules
Article Snippet: In brief, a single tumor fragment was placed in individual wells of a 24-well tissue culture plate with 2 mL of complete medium (CM) plus 6000 IU per mL of rhIL-2 (Chiron Corp., Emeryville, CA).

Purification:

Article Title: Evolution of melanoma cross-resistance to CD8 + T cells and MAPK inhibition in the course of BRAFi treatment
Article Snippet: Expansion of TILs was achieved by culturing suspension cells from tumor tissue in RPMI 1640 supplemented with 10% FCS, penicillin/streptomycin, and 500 IU/ml rhIL-2 (Chiron Corporation) for 2–5 weeks.

Article Title: The IL-2 SYNTHORIN molecule promotes functionally adapted Tregs in a preclinical model of type 1 diabetes.
Article Snippet: To investigate the in vitro effects of SAR’336 (Sanofi) on Tregs, purified CD4+GFP+ Tregs (GFP+, 50 × 103) from B6.FoxP3GFPki female mice were activated in 96-well, flat-bottomed (0.2 mL) plates previously coated with α-CD3 (3 μg/mL) and α-CD28 (2 μg/mL), in the presence of rhIL-2 (1 μg/mL; Chiron Corporation) or SAR’336 (1 μg/mL) in RPMI supplemented with 10% FBS at 37°C for 72 hours.

Article Title: The IL-2 SYNTHORIN molecule promotes functionally adapted Tregs in a preclinical model of type 1 diabetes
Article Snippet: To investigate the in vitro effects of SAR’336 (Sanofi) on Tregs, purified CD4 + GFP + Tregs (GFP + , 50 × 10 3 ) from B6.FoxP3 GFPki female mice were activated in 96-well, flat-bottomed (0.2 mL) plates previously coated with α-CD3 (3 μg/mL) and α-CD28 (2 μg/mL), in the presence of rhIL-2 (1 μg/mL; Chiron Corporation) or SAR’336 (1 μg/mL) in RPMI supplemented with 10% FBS at 37°C for 72 hours.

Article Title: Genetically engineered macrophages persist in solid tumors and locally deliver therapeutic proteins to activate immune responses
Article Snippet: T cells were stimulated with Dynabeads and cultured in RPMI-1640 (Gibco) with 10% FBS (VWR Seradigm), 2 mM l-glutamine (Gibco), 0.5 ng/mL rhIL-15 (Miltenyi Biotec) and either 50 U/mL rhIL-2 (CD8 + T cells; Chiron Corporation) or 5 ng/mL rhIL-7 (CD4 + T cells; Miltenyi Biotec).

Article Title: Cancer-Initiating Cells from Colorectal Cancer Patients Escape from T Cell–Mediated Immunosurveillance In Vitro through Membrane-Bound IL-4
Article Snippet: IL-4 neutralization can augment the proliferation of MLTCs stimulated with autologous CICs Isolation of CRC-reactive T lymphocytes PBMCs from the peripheral blood of CRC patients (#1076, 1247, and 14583) were cultured in vitro in the presence of autologous irradiated (300 Gy) colorectal CICs or, when available, FBS tumor cells, pretreated or not with rhIFN-γ (1000 IU/ml; PeproTech), with 100 IU/ml rhIL-2 (Chiron Corporation, Emeryville, CA) and 10 ng/ml rhIL-7 (PeproTech) in X-VIVO-15 (Cambrex, Lonza, Basel, Switzerland) plus 5% human serum.

Article Title: Cancer-Initiating Cells from Colorectal Cancer Patients Escape from T Cell–Mediated Immunosurveillance In Vitro through Membrane-Bound IL-4
Article Snippet: PBMCs from the peripheral blood of CRC patients (#1076, 1247, and 14583) were cultured in vitro in the presence of autologous irradiated (300 Gy) colorectal CICs or, when available, FBS tumor cells, pretreated or not with rhIFN-γ (1000 IU/ml; PeproTech), with 100 IU/ml rhIL-2 (Chiron Corporation, Emeryville, CA) and 10 ng/ml rhIL-7 (PeproTech) in X-VIVO-15 (Cambrex, Lonza, Basel, Switzerland) plus 5% human serum.

Article Title: Genetically engineered macrophages persist in solid tumors and locally deliver therapeutic proteins to activate immune responses.
Article Snippet: T cells were stimulated with Dynabeads and cultured in RPMI-1640 (Gibco) with 10% FBS (VWR Seradigm), 2 mM l- glutamine (Gibco), 0.5 ng/mL rhIL-15 (Miltenyi Biotec) and either 50 U/ mL rhIL-2 (CD8+ T cells; Chiron Corporation) or 5 ng/ mL rhIL-7 (CD4+ T cells; Miltenyi Biotec).

Article Title: Modulation of SRSF2 expression reverses the exhaustion of TILs via the epigenetic regulation of immune checkpoint molecules
Article Snippet: In brief, a single tumor fragment was placed in individual wells of a 24-well tissue culture plate with 2 mL of complete medium (CM) plus 6000 IU per mL of rhIL-2 (Chiron Corp., Emeryville, CA).

Labeling:

Article Title: Evolution of melanoma cross-resistance to CD8 + T cells and MAPK inhibition in the course of BRAFi treatment
Article Snippet: Expansion of TILs was achieved by culturing suspension cells from tumor tissue in RPMI 1640 supplemented with 10% FCS, penicillin/streptomycin, and 500 IU/ml rhIL-2 (Chiron Corporation) for 2–5 weeks.

Article Title: The IL-2 SYNTHORIN molecule promotes functionally adapted Tregs in a preclinical model of type 1 diabetes.
Article Snippet: To investigate the in vitro effects of SAR’336 (Sanofi) on Tregs, purified CD4+GFP+ Tregs (GFP+, 50 × 103) from B6.FoxP3GFPki female mice were activated in 96-well, flat-bottomed (0.2 mL) plates previously coated with α-CD3 (3 μg/mL) and α-CD28 (2 μg/mL), in the presence of rhIL-2 (1 μg/mL; Chiron Corporation) or SAR’336 (1 μg/mL) in RPMI supplemented with 10% FBS at 37°C for 72 hours.

Article Title: The IL-2 SYNTHORIN molecule promotes functionally adapted Tregs in a preclinical model of type 1 diabetes
Article Snippet: To investigate the in vitro effects of SAR’336 (Sanofi) on Tregs, purified CD4 + GFP + Tregs (GFP + , 50 × 10 3 ) from B6.FoxP3 GFPki female mice were activated in 96-well, flat-bottomed (0.2 mL) plates previously coated with α-CD3 (3 μg/mL) and α-CD28 (2 μg/mL), in the presence of rhIL-2 (1 μg/mL; Chiron Corporation) or SAR’336 (1 μg/mL) in RPMI supplemented with 10% FBS at 37°C for 72 hours.

Article Title: Genetically engineered macrophages persist in solid tumors and locally deliver therapeutic proteins to activate immune responses
Article Snippet: T cells were stimulated with Dynabeads and cultured in RPMI-1640 (Gibco) with 10% FBS (VWR Seradigm), 2 mM l-glutamine (Gibco), 0.5 ng/mL rhIL-15 (Miltenyi Biotec) and either 50 U/mL rhIL-2 (CD8 + T cells; Chiron Corporation) or 5 ng/mL rhIL-7 (CD4 + T cells; Miltenyi Biotec).

Article Title: Cancer-Initiating Cells from Colorectal Cancer Patients Escape from T Cell–Mediated Immunosurveillance In Vitro through Membrane-Bound IL-4
Article Snippet: IL-4 neutralization can augment the proliferation of MLTCs stimulated with autologous CICs Isolation of CRC-reactive T lymphocytes PBMCs from the peripheral blood of CRC patients (#1076, 1247, and 14583) were cultured in vitro in the presence of autologous irradiated (300 Gy) colorectal CICs or, when available, FBS tumor cells, pretreated or not with rhIFN-γ (1000 IU/ml; PeproTech), with 100 IU/ml rhIL-2 (Chiron Corporation, Emeryville, CA) and 10 ng/ml rhIL-7 (PeproTech) in X-VIVO-15 (Cambrex, Lonza, Basel, Switzerland) plus 5% human serum.

Article Title: Cancer-Initiating Cells from Colorectal Cancer Patients Escape from T Cell–Mediated Immunosurveillance In Vitro through Membrane-Bound IL-4
Article Snippet: PBMCs from the peripheral blood of CRC patients (#1076, 1247, and 14583) were cultured in vitro in the presence of autologous irradiated (300 Gy) colorectal CICs or, when available, FBS tumor cells, pretreated or not with rhIFN-γ (1000 IU/ml; PeproTech), with 100 IU/ml rhIL-2 (Chiron Corporation, Emeryville, CA) and 10 ng/ml rhIL-7 (PeproTech) in X-VIVO-15 (Cambrex, Lonza, Basel, Switzerland) plus 5% human serum.

Article Title: Genetically engineered macrophages persist in solid tumors and locally deliver therapeutic proteins to activate immune responses.
Article Snippet: T cells were stimulated with Dynabeads and cultured in RPMI-1640 (Gibco) with 10% FBS (VWR Seradigm), 2 mM l- glutamine (Gibco), 0.5 ng/mL rhIL-15 (Miltenyi Biotec) and either 50 U/ mL rhIL-2 (CD8+ T cells; Chiron Corporation) or 5 ng/ mL rhIL-7 (CD4+ T cells; Miltenyi Biotec).

Article Title: Modulation of SRSF2 expression reverses the exhaustion of TILs via the epigenetic regulation of immune checkpoint molecules
Article Snippet: In brief, a single tumor fragment was placed in individual wells of a 24-well tissue culture plate with 2 mL of complete medium (CM) plus 6000 IU per mL of rhIL-2 (Chiron Corp., Emeryville, CA).

Neutralization:

Article Title: Evolution of melanoma cross-resistance to CD8 + T cells and MAPK inhibition in the course of BRAFi treatment
Article Snippet: Expansion of TILs was achieved by culturing suspension cells from tumor tissue in RPMI 1640 supplemented with 10% FCS, penicillin/streptomycin, and 500 IU/ml rhIL-2 (Chiron Corporation) for 2–5 weeks.

Article Title: The IL-2 SYNTHORIN molecule promotes functionally adapted Tregs in a preclinical model of type 1 diabetes.
Article Snippet: To investigate the in vitro effects of SAR’336 (Sanofi) on Tregs, purified CD4+GFP+ Tregs (GFP+, 50 × 103) from B6.FoxP3GFPki female mice were activated in 96-well, flat-bottomed (0.2 mL) plates previously coated with α-CD3 (3 μg/mL) and α-CD28 (2 μg/mL), in the presence of rhIL-2 (1 μg/mL; Chiron Corporation) or SAR’336 (1 μg/mL) in RPMI supplemented with 10% FBS at 37°C for 72 hours.

Article Title: The IL-2 SYNTHORIN molecule promotes functionally adapted Tregs in a preclinical model of type 1 diabetes
Article Snippet: To investigate the in vitro effects of SAR’336 (Sanofi) on Tregs, purified CD4 + GFP + Tregs (GFP + , 50 × 10 3 ) from B6.FoxP3 GFPki female mice were activated in 96-well, flat-bottomed (0.2 mL) plates previously coated with α-CD3 (3 μg/mL) and α-CD28 (2 μg/mL), in the presence of rhIL-2 (1 μg/mL; Chiron Corporation) or SAR’336 (1 μg/mL) in RPMI supplemented with 10% FBS at 37°C for 72 hours.

Article Title: Genetically engineered macrophages persist in solid tumors and locally deliver therapeutic proteins to activate immune responses
Article Snippet: T cells were stimulated with Dynabeads and cultured in RPMI-1640 (Gibco) with 10% FBS (VWR Seradigm), 2 mM l-glutamine (Gibco), 0.5 ng/mL rhIL-15 (Miltenyi Biotec) and either 50 U/mL rhIL-2 (CD8 + T cells; Chiron Corporation) or 5 ng/mL rhIL-7 (CD4 + T cells; Miltenyi Biotec).

Article Title: Cancer-Initiating Cells from Colorectal Cancer Patients Escape from T Cell–Mediated Immunosurveillance In Vitro through Membrane-Bound IL-4
Article Snippet: IL-4 neutralization can augment the proliferation of MLTCs stimulated with autologous CICs Isolation of CRC-reactive T lymphocytes PBMCs from the peripheral blood of CRC patients (#1076, 1247, and 14583) were cultured in vitro in the presence of autologous irradiated (300 Gy) colorectal CICs or, when available, FBS tumor cells, pretreated or not with rhIFN-γ (1000 IU/ml; PeproTech), with 100 IU/ml rhIL-2 (Chiron Corporation, Emeryville, CA) and 10 ng/ml rhIL-7 (PeproTech) in X-VIVO-15 (Cambrex, Lonza, Basel, Switzerland) plus 5% human serum.

Article Title: Cancer-Initiating Cells from Colorectal Cancer Patients Escape from T Cell–Mediated Immunosurveillance In Vitro through Membrane-Bound IL-4
Article Snippet: PBMCs from the peripheral blood of CRC patients (#1076, 1247, and 14583) were cultured in vitro in the presence of autologous irradiated (300 Gy) colorectal CICs or, when available, FBS tumor cells, pretreated or not with rhIFN-γ (1000 IU/ml; PeproTech), with 100 IU/ml rhIL-2 (Chiron Corporation, Emeryville, CA) and 10 ng/ml rhIL-7 (PeproTech) in X-VIVO-15 (Cambrex, Lonza, Basel, Switzerland) plus 5% human serum.

Article Title: Genetically engineered macrophages persist in solid tumors and locally deliver therapeutic proteins to activate immune responses.
Article Snippet: T cells were stimulated with Dynabeads and cultured in RPMI-1640 (Gibco) with 10% FBS (VWR Seradigm), 2 mM l- glutamine (Gibco), 0.5 ng/mL rhIL-15 (Miltenyi Biotec) and either 50 U/ mL rhIL-2 (CD8+ T cells; Chiron Corporation) or 5 ng/ mL rhIL-7 (CD4+ T cells; Miltenyi Biotec).

Article Title: Modulation of SRSF2 expression reverses the exhaustion of TILs via the epigenetic regulation of immune checkpoint molecules
Article Snippet: In brief, a single tumor fragment was placed in individual wells of a 24-well tissue culture plate with 2 mL of complete medium (CM) plus 6000 IU per mL of rhIL-2 (Chiron Corp., Emeryville, CA).

Isolation:

Article Title: Evolution of melanoma cross-resistance to CD8 + T cells and MAPK inhibition in the course of BRAFi treatment
Article Snippet: Expansion of TILs was achieved by culturing suspension cells from tumor tissue in RPMI 1640 supplemented with 10% FCS, penicillin/streptomycin, and 500 IU/ml rhIL-2 (Chiron Corporation) for 2–5 weeks.

Article Title: The IL-2 SYNTHORIN molecule promotes functionally adapted Tregs in a preclinical model of type 1 diabetes.
Article Snippet: To investigate the in vitro effects of SAR’336 (Sanofi) on Tregs, purified CD4+GFP+ Tregs (GFP+, 50 × 103) from B6.FoxP3GFPki female mice were activated in 96-well, flat-bottomed (0.2 mL) plates previously coated with α-CD3 (3 μg/mL) and α-CD28 (2 μg/mL), in the presence of rhIL-2 (1 μg/mL; Chiron Corporation) or SAR’336 (1 μg/mL) in RPMI supplemented with 10% FBS at 37°C for 72 hours.

Article Title: The IL-2 SYNTHORIN molecule promotes functionally adapted Tregs in a preclinical model of type 1 diabetes
Article Snippet: To investigate the in vitro effects of SAR’336 (Sanofi) on Tregs, purified CD4 + GFP + Tregs (GFP + , 50 × 10 3 ) from B6.FoxP3 GFPki female mice were activated in 96-well, flat-bottomed (0.2 mL) plates previously coated with α-CD3 (3 μg/mL) and α-CD28 (2 μg/mL), in the presence of rhIL-2 (1 μg/mL; Chiron Corporation) or SAR’336 (1 μg/mL) in RPMI supplemented with 10% FBS at 37°C for 72 hours.

Article Title: Genetically engineered macrophages persist in solid tumors and locally deliver therapeutic proteins to activate immune responses
Article Snippet: T cells were stimulated with Dynabeads and cultured in RPMI-1640 (Gibco) with 10% FBS (VWR Seradigm), 2 mM l-glutamine (Gibco), 0.5 ng/mL rhIL-15 (Miltenyi Biotec) and either 50 U/mL rhIL-2 (CD8 + T cells; Chiron Corporation) or 5 ng/mL rhIL-7 (CD4 + T cells; Miltenyi Biotec).

Article Title: Cancer-Initiating Cells from Colorectal Cancer Patients Escape from T Cell–Mediated Immunosurveillance In Vitro through Membrane-Bound IL-4
Article Snippet: IL-4 neutralization can augment the proliferation of MLTCs stimulated with autologous CICs Isolation of CRC-reactive T lymphocytes PBMCs from the peripheral blood of CRC patients (#1076, 1247, and 14583) were cultured in vitro in the presence of autologous irradiated (300 Gy) colorectal CICs or, when available, FBS tumor cells, pretreated or not with rhIFN-γ (1000 IU/ml; PeproTech), with 100 IU/ml rhIL-2 (Chiron Corporation, Emeryville, CA) and 10 ng/ml rhIL-7 (PeproTech) in X-VIVO-15 (Cambrex, Lonza, Basel, Switzerland) plus 5% human serum.

Article Title: Cancer-Initiating Cells from Colorectal Cancer Patients Escape from T Cell–Mediated Immunosurveillance In Vitro through Membrane-Bound IL-4
Article Snippet: PBMCs from the peripheral blood of CRC patients (#1076, 1247, and 14583) were cultured in vitro in the presence of autologous irradiated (300 Gy) colorectal CICs or, when available, FBS tumor cells, pretreated or not with rhIFN-γ (1000 IU/ml; PeproTech), with 100 IU/ml rhIL-2 (Chiron Corporation, Emeryville, CA) and 10 ng/ml rhIL-7 (PeproTech) in X-VIVO-15 (Cambrex, Lonza, Basel, Switzerland) plus 5% human serum.

Article Title: Genetically engineered macrophages persist in solid tumors and locally deliver therapeutic proteins to activate immune responses.
Article Snippet: T cells were stimulated with Dynabeads and cultured in RPMI-1640 (Gibco) with 10% FBS (VWR Seradigm), 2 mM l- glutamine (Gibco), 0.5 ng/mL rhIL-15 (Miltenyi Biotec) and either 50 U/ mL rhIL-2 (CD8+ T cells; Chiron Corporation) or 5 ng/ mL rhIL-7 (CD4+ T cells; Miltenyi Biotec).

Article Title: Modulation of SRSF2 expression reverses the exhaustion of TILs via the epigenetic regulation of immune checkpoint molecules
Article Snippet: In brief, a single tumor fragment was placed in individual wells of a 24-well tissue culture plate with 2 mL of complete medium (CM) plus 6000 IU per mL of rhIL-2 (Chiron Corp., Emeryville, CA).

Cell Culture:

Article Title: Evolution of melanoma cross-resistance to CD8 + T cells and MAPK inhibition in the course of BRAFi treatment
Article Snippet: Expansion of TILs was achieved by culturing suspension cells from tumor tissue in RPMI 1640 supplemented with 10% FCS, penicillin/streptomycin, and 500 IU/ml rhIL-2 (Chiron Corporation) for 2–5 weeks.

Article Title: The IL-2 SYNTHORIN molecule promotes functionally adapted Tregs in a preclinical model of type 1 diabetes.
Article Snippet: To investigate the in vitro effects of SAR’336 (Sanofi) on Tregs, purified CD4+GFP+ Tregs (GFP+, 50 × 103) from B6.FoxP3GFPki female mice were activated in 96-well, flat-bottomed (0.2 mL) plates previously coated with α-CD3 (3 μg/mL) and α-CD28 (2 μg/mL), in the presence of rhIL-2 (1 μg/mL; Chiron Corporation) or SAR’336 (1 μg/mL) in RPMI supplemented with 10% FBS at 37°C for 72 hours.

Article Title: The IL-2 SYNTHORIN molecule promotes functionally adapted Tregs in a preclinical model of type 1 diabetes
Article Snippet: To investigate the in vitro effects of SAR’336 (Sanofi) on Tregs, purified CD4 + GFP + Tregs (GFP + , 50 × 10 3 ) from B6.FoxP3 GFPki female mice were activated in 96-well, flat-bottomed (0.2 mL) plates previously coated with α-CD3 (3 μg/mL) and α-CD28 (2 μg/mL), in the presence of rhIL-2 (1 μg/mL; Chiron Corporation) or SAR’336 (1 μg/mL) in RPMI supplemented with 10% FBS at 37°C for 72 hours.

Article Title: Genetically engineered macrophages persist in solid tumors and locally deliver therapeutic proteins to activate immune responses
Article Snippet: T cells were stimulated with Dynabeads and cultured in RPMI-1640 (Gibco) with 10% FBS (VWR Seradigm), 2 mM l-glutamine (Gibco), 0.5 ng/mL rhIL-15 (Miltenyi Biotec) and either 50 U/mL rhIL-2 (CD8 + T cells; Chiron Corporation) or 5 ng/mL rhIL-7 (CD4 + T cells; Miltenyi Biotec).

Article Title: Cancer-Initiating Cells from Colorectal Cancer Patients Escape from T Cell–Mediated Immunosurveillance In Vitro through Membrane-Bound IL-4
Article Snippet: IL-4 neutralization can augment the proliferation of MLTCs stimulated with autologous CICs Isolation of CRC-reactive T lymphocytes PBMCs from the peripheral blood of CRC patients (#1076, 1247, and 14583) were cultured in vitro in the presence of autologous irradiated (300 Gy) colorectal CICs or, when available, FBS tumor cells, pretreated or not with rhIFN-γ (1000 IU/ml; PeproTech), with 100 IU/ml rhIL-2 (Chiron Corporation, Emeryville, CA) and 10 ng/ml rhIL-7 (PeproTech) in X-VIVO-15 (Cambrex, Lonza, Basel, Switzerland) plus 5% human serum.

Article Title: Cancer-Initiating Cells from Colorectal Cancer Patients Escape from T Cell–Mediated Immunosurveillance In Vitro through Membrane-Bound IL-4
Article Snippet: PBMCs from the peripheral blood of CRC patients (#1076, 1247, and 14583) were cultured in vitro in the presence of autologous irradiated (300 Gy) colorectal CICs or, when available, FBS tumor cells, pretreated or not with rhIFN-γ (1000 IU/ml; PeproTech), with 100 IU/ml rhIL-2 (Chiron Corporation, Emeryville, CA) and 10 ng/ml rhIL-7 (PeproTech) in X-VIVO-15 (Cambrex, Lonza, Basel, Switzerland) plus 5% human serum.

Article Title: Genetically engineered macrophages persist in solid tumors and locally deliver therapeutic proteins to activate immune responses.
Article Snippet: T cells were stimulated with Dynabeads and cultured in RPMI-1640 (Gibco) with 10% FBS (VWR Seradigm), 2 mM l- glutamine (Gibco), 0.5 ng/mL rhIL-15 (Miltenyi Biotec) and either 50 U/ mL rhIL-2 (CD8+ T cells; Chiron Corporation) or 5 ng/ mL rhIL-7 (CD4+ T cells; Miltenyi Biotec).

Article Title: Modulation of SRSF2 expression reverses the exhaustion of TILs via the epigenetic regulation of immune checkpoint molecules
Article Snippet: In brief, a single tumor fragment was placed in individual wells of a 24-well tissue culture plate with 2 mL of complete medium (CM) plus 6000 IU per mL of rhIL-2 (Chiron Corp., Emeryville, CA).

Irradiation:

Article Title: Evolution of melanoma cross-resistance to CD8 + T cells and MAPK inhibition in the course of BRAFi treatment
Article Snippet: Expansion of TILs was achieved by culturing suspension cells from tumor tissue in RPMI 1640 supplemented with 10% FCS, penicillin/streptomycin, and 500 IU/ml rhIL-2 (Chiron Corporation) for 2–5 weeks.

Article Title: The IL-2 SYNTHORIN molecule promotes functionally adapted Tregs in a preclinical model of type 1 diabetes.
Article Snippet: To investigate the in vitro effects of SAR’336 (Sanofi) on Tregs, purified CD4+GFP+ Tregs (GFP+, 50 × 103) from B6.FoxP3GFPki female mice were activated in 96-well, flat-bottomed (0.2 mL) plates previously coated with α-CD3 (3 μg/mL) and α-CD28 (2 μg/mL), in the presence of rhIL-2 (1 μg/mL; Chiron Corporation) or SAR’336 (1 μg/mL) in RPMI supplemented with 10% FBS at 37°C for 72 hours.

Article Title: The IL-2 SYNTHORIN molecule promotes functionally adapted Tregs in a preclinical model of type 1 diabetes
Article Snippet: To investigate the in vitro effects of SAR’336 (Sanofi) on Tregs, purified CD4 + GFP + Tregs (GFP + , 50 × 10 3 ) from B6.FoxP3 GFPki female mice were activated in 96-well, flat-bottomed (0.2 mL) plates previously coated with α-CD3 (3 μg/mL) and α-CD28 (2 μg/mL), in the presence of rhIL-2 (1 μg/mL; Chiron Corporation) or SAR’336 (1 μg/mL) in RPMI supplemented with 10% FBS at 37°C for 72 hours.

Article Title: Genetically engineered macrophages persist in solid tumors and locally deliver therapeutic proteins to activate immune responses
Article Snippet: T cells were stimulated with Dynabeads and cultured in RPMI-1640 (Gibco) with 10% FBS (VWR Seradigm), 2 mM l-glutamine (Gibco), 0.5 ng/mL rhIL-15 (Miltenyi Biotec) and either 50 U/mL rhIL-2 (CD8 + T cells; Chiron Corporation) or 5 ng/mL rhIL-7 (CD4 + T cells; Miltenyi Biotec).

Article Title: Cancer-Initiating Cells from Colorectal Cancer Patients Escape from T Cell–Mediated Immunosurveillance In Vitro through Membrane-Bound IL-4
Article Snippet: IL-4 neutralization can augment the proliferation of MLTCs stimulated with autologous CICs Isolation of CRC-reactive T lymphocytes PBMCs from the peripheral blood of CRC patients (#1076, 1247, and 14583) were cultured in vitro in the presence of autologous irradiated (300 Gy) colorectal CICs or, when available, FBS tumor cells, pretreated or not with rhIFN-γ (1000 IU/ml; PeproTech), with 100 IU/ml rhIL-2 (Chiron Corporation, Emeryville, CA) and 10 ng/ml rhIL-7 (PeproTech) in X-VIVO-15 (Cambrex, Lonza, Basel, Switzerland) plus 5% human serum.

Article Title: Cancer-Initiating Cells from Colorectal Cancer Patients Escape from T Cell–Mediated Immunosurveillance In Vitro through Membrane-Bound IL-4
Article Snippet: PBMCs from the peripheral blood of CRC patients (#1076, 1247, and 14583) were cultured in vitro in the presence of autologous irradiated (300 Gy) colorectal CICs or, when available, FBS tumor cells, pretreated or not with rhIFN-γ (1000 IU/ml; PeproTech), with 100 IU/ml rhIL-2 (Chiron Corporation, Emeryville, CA) and 10 ng/ml rhIL-7 (PeproTech) in X-VIVO-15 (Cambrex, Lonza, Basel, Switzerland) plus 5% human serum.

Article Title: Genetically engineered macrophages persist in solid tumors and locally deliver therapeutic proteins to activate immune responses.
Article Snippet: T cells were stimulated with Dynabeads and cultured in RPMI-1640 (Gibco) with 10% FBS (VWR Seradigm), 2 mM l- glutamine (Gibco), 0.5 ng/mL rhIL-15 (Miltenyi Biotec) and either 50 U/ mL rhIL-2 (CD8+ T cells; Chiron Corporation) or 5 ng/ mL rhIL-7 (CD4+ T cells; Miltenyi Biotec).

Article Title: Modulation of SRSF2 expression reverses the exhaustion of TILs via the epigenetic regulation of immune checkpoint molecules
Article Snippet: In brief, a single tumor fragment was placed in individual wells of a 24-well tissue culture plate with 2 mL of complete medium (CM) plus 6000 IU per mL of rhIL-2 (Chiron Corp., Emeryville, CA).



Similar Products

86
Novartis human il 2 rhil 2
Human Il 2 Rhil 2, supplied by Novartis, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rhil-2/2+human+il/pm42132875-357-75-79
Average 86 stars, based on 1 article reviews
human il 2 rhil 2 - by Bioz Stars, 2026-09
86/100 stars
  Buy from Supplier

86
Clinigen Inc rhil 2
Rhil 2, supplied by Clinigen Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rhil-2/2+rhil/10__1097_slash_cji__0000000000000607-20-44-45
Average 86 stars, based on 1 article reviews
rhil 2 - by Bioz Stars, 2026-09
86/100 stars
  Buy from Supplier

96
R&D Systems rhil 7
Rhil 7, supplied by R&D Systems, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rhil-2/Recombinant+Human+IL-2+Protein/pmc13089343-228-47-50
Average 96 stars, based on 1 article reviews
rhil 7 - by Bioz Stars, 2026-09
96/100 stars
  Buy from Supplier

96
R&D Systems rhil 2
Rhil 2, supplied by R&D Systems, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rhil-2/Recombinant+Human+IL-2+Protein/pmc13089343-228-41-44
Average 96 stars, based on 1 article reviews
rhil 2 - by Bioz Stars, 2026-09
96/100 stars
  Buy from Supplier

86
Novartis rhil 2
Rhil 2, supplied by Novartis, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rhil-2/2+rhil/us12590163-2096-34-38
Average 86 stars, based on 1 article reviews
rhil 2 - by Bioz Stars, 2026-09
86/100 stars
  Buy from Supplier

86
Novartis recombinant human il 2 rhil 2
Recombinant Human Il 2 Rhil 2, supplied by Novartis, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rhil-2/2+human+il/pmc12982053-61-23-27
Average 86 stars, based on 1 article reviews
recombinant human il 2 rhil 2 - by Bioz Stars, 2026-09
86/100 stars
  Buy from Supplier

86
Chiron Corporation rhil 2
Rhil 2, supplied by Chiron Corporation, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rhil-2/2+rhil/us12533338-31-16-18
Average 86 stars, based on 1 article reviews
rhil 2 - by Bioz Stars, 2026-09
86/100 stars
  Buy from Supplier

Image Search Results